We love Amylin Pharmaceuticals, and a lot of other people should love them too. They’re a rising-star type of company in the treatment of diabetes, obesity and cardiovascular disease. Walk down any street in America and it’s easy to see the prevalence of these dangerous health problems. Not every company out there makes a real difference in peoples’ lives…but Amylin actually does.
We’ve been working with them for two years as part of a multi-agency partnership to develop and manage the company’s relationships with key industry opinion leaders (prominent practicing and academic physicians that are heavily involved in scientific research, clinical trial investigation, and who speak and write extensively on developments in these disease areas).
The cornerstone of our program is a magnet web property known as “CREATUS” (the Latin for “to create”). It’s a members-only portal rich in scientific media and other resources, delivering breaking news, clinical information and the latest discovery research from every legitimate outlet around the globe – not just from Amylin. Unique in its non-promotional tone and democratic approach to inclusion of industry-wide content, we think it will become the new model for building strong physician relationships in the post-advertising era we’re living in today.
